Radiotherapy
Short-term efficacy and adverse events of intensity-modulated radiotherapy combined with chronomodulated chemotherapy for locally advanced nasopharyngeal carcinoma
Jiang Hang, Jin Feng, Wu Weili, Li Yuanyuan, Long Jinhua, Gong Xiuyun, Chen Xiaoxiao, Gan Jiaying, Li Zhuoling
Published 2019-11-25
Cite as Chin J Radiol Med Prot, 2019,39(11): 813-819. DOI: 10.3760/cma.j.issn.0254-5098.2019.11.003
Abstract
ObjectiveTo compare the adverse events, immune status, and short-term efficacy between chronomodulated chemotherapy (CCR) and routine chemotherapy (RCR) combined with intensity modulated radiotherapy (IMRT)in the treatment of patients with locally advanced nasopharyngeal carcinoma.
MethodsA total of 159 patients with newly diagnosed locally advanced nasopharyngeal carcinoma were randomized into the CCR group and the RCR group to evaluate the short-term efficacy and adverse events.
ResultsNo significant difference was found in CR, PR, SD, and PD between the CCR group and the RCR group (P>0.05), and no significant difference was observed in the response rate (CR+ PR) between the two groups (P>0.05). The incidence of leukopenia(Z=-2.222, P<0.05), neutropenia(Z=-1.999, P<0.05), vomiting(Z=-2.298, P<0.05), and oral mucositis(Z=-3.571, P<0.05)of the CCR group was lower than those of the RCR group with statistical significance. The CD16+ 56+ lymphocyte cell count was higher in the CCR group than that in the RCR group(Z=-2.332, P<0.05).
ConclusionsAs a novel invention, CCR combined with IMRT can reduce the incidence and severity of treatment-related adverse events and improve immune status without diminishing clinical efficacy, therefore deserving clinical application.
Key words:
Nasopharyngeal carcinoma; Chronomodulated chemotherapy; Intensity-modulated radiotherapy; Adverse events; Short-term efficacy
Contributor Information
Jiang Hang
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Jin Feng
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Wu Weili
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Li Yuanyuan
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Long Jinhua
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Gong Xiuyun
The Affiliated Cancer Hospital of Guizhou Medical University, Department of Head and Neck Oncology/Guizhou Cancer Hospital, Guiyang 550004, China
Chen Xiaoxiao
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Gan Jiaying
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
Li Zhuoling
Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
